Yilmaz U, Polat G, Anar C, Halilcolar H
Department of Pulmonary Medicine, Suat Seren Chest Disease and Surgery Training and Research Hospital, Izmir, Turkey.
Indian J Cancer. 2011 Oct-Dec;48(4):454-9. doi: 10.4103/0019-509X.92279.
The aim of this study is to investigate the activity and toxicity of etoposide with AUC 6 doses of carboplatin in patients with previously untreated extensive disease - small-cell lung cancer (SCLC).
88 eligible patients were treated with chemotherapy comprised of carboplatin AUC of 6, IV day 1 and etoposide 100 mg/m 2 , IV day 1-3. This schedule was repeated every 21 days for maximum of six cycles.
Patients characteristics: Median age, 62 years; 84 male; ECOG PS 0-1 in 73 patients, PS 2-3 in 15 patients. A total of 431 cycles were administered (median, 6.0). The complete and partial response rates were 23.9% and 45.5%, respectively. Median overall survival (OS) was 9.0 months (95% confidence interval [CI], 8.09 - 9.90 m); 84 patients died. The 1- and 2-year survival probabilities were 33.6% and 5.3%, respectively. The median progression-free survival in patients of 65 was 7.2 months (95% CI, 5.81 - 8.58), 12-month PFS rate was 10%. The median OS was 11.6 months (95% CI, 8.52 - 14.67 m) and 7.5 months (95% CI, 5.61 - 9.38 m) in patients with non-liver and liver metastasis, respectively (P = 0.024). The median OS was 9.3 months (95% CI, 7.83 - 10.76 m) and 7.5 months (95% CI, 5.58 - 9.44 m) in patients with single and multiple distant metastasis, respectively (P = 0.02). Grade 3-4 neutropenia, thrombocytopenia, and anemia were detected in 57.9%, 15.9%, and 11.4% of patients, respectively. Febrile neutropenia was developed in 12 patients.
Etoposide with AUC 6 doses of carboplatin is active and tolerable in patients with extensive disease - SCLC.
本研究旨在调查依托泊苷联合6个AUC剂量卡铂治疗既往未经治疗的广泛期小细胞肺癌（SCLC）患者的活性和毒性。
88例符合条件的患者接受化疗，化疗方案为第1天静脉滴注卡铂AUC 6，第1 - 3天静脉滴注依托泊苷100 mg/m²。每21天重复此方案，最多6个周期。
患者特征：中位年龄62岁；男性84例；73例患者东部肿瘤协作组（ECOG）体能状态（PS）为0 - 1，15例患者PS为2 - 3。共进行了431个周期（中位周期数为6.0）。完全缓解率和部分缓解率分别为23.9%和45.5%。中位总生存期（OS）为9.0个月（95%置信区间[CI]，8.09 - 9.90个月）；84例患者死亡。1年和2年生存率分别为33.6%和5.3%。65岁患者的中位无进展生存期为7.2个月（95% CI，5.81 - 8.58），12个月无进展生存率为10%。无肝转移和有肝转移患者的中位OS分别为11.6个月（95% CI，8.52 - 14.67个月）和7.5个月（95% CI，5.61 - 9.38个月）（P = 0.024）。单发和多发远处转移患者的中位OS分别为9.3个月（95% CI，7.83 - 10.76个月）和7.5个月（95% CI，5.58 - 9.44个月）（P = 0.02）。分别有57.9%、15.9%和11.4%的患者出现3 - 4级中性粒细胞减少、血小板减少和贫血。12例患者发生发热性中性粒细胞减少。
依托泊苷联合6个AUC剂量卡铂治疗广泛期SCLC患者具有活性且耐受性良好。
